187 related articles for article (PubMed ID: 29499065)
1. High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.
Yu KK; Taylor JT; Pathmanaban ON; Youshani AS; Beyit D; Dutko-Gwozdz J; Benson R; Griffiths G; Peers I; Cueppens P; Telfer BA; Williams KJ; McBain C; Kamaly-Asl ID; Bigger BW
PLoS One; 2018; 13(3):e0193694. PubMed ID: 29499065
[TBL] [Abstract][Full Text] [Related]
2. A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.
Gomez-Roman N; Stevenson K; Gilmour L; Hamilton G; Chalmers AJ
Neuro Oncol; 2017 Feb; 19(2):229-241. PubMed ID: 27576873
[TBL] [Abstract][Full Text] [Related]
3. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.
Hothi P; Martins TJ; Chen L; Deleyrolle L; Yoon JG; Reynolds B; Foltz G
Oncotarget; 2012 Oct; 3(10):1124-36. PubMed ID: 23165409
[TBL] [Abstract][Full Text] [Related]
4. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.
Skaga E; Kulesskiy E; Fayzullin A; Sandberg CJ; Potdar S; Kyttälä A; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO
BMC Cancer; 2019 Jun; 19(1):628. PubMed ID: 31238897
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis.
Buccarelli M; Marconi M; Pacioni S; De Pascalis I; D'Alessandris QG; Martini M; Ascione B; Malorni W; Larocca LM; Pallini R; Ricci-Vitiani L; Matarrese P
Cell Death Dis; 2018 Aug; 9(8):841. PubMed ID: 30082680
[TBL] [Abstract][Full Text] [Related]
6. Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma.
Taylor JT; Ellison S; Pandele A; Wood S; Nathan E; Forte G; Parker H; Zindy E; Elvin M; Dickson A; Williams KJ; Karabatsou K; McCabe M; McBain C; Bigger BW
Neuro Oncol; 2020 Sep; 22(9):1289-1301. PubMed ID: 32227096
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.
Riedel M; Struve N; Müller-Goebel J; Köcher S; Petersen C; Dikomey E; Rothkamm K; Kriegs M
Oncotarget; 2016 Sep; 7(38):61988-61995. PubMed ID: 27542273
[TBL] [Abstract][Full Text] [Related]
8. Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance.
Atkins RJ; Stylli SS; Kurganovs N; Mangiola S; Nowell CJ; Ware TM; Corcoran NM; Brown DV; Kaye AH; Morokoff A; Luwor RB; Hovens CM; Mantamadiotis T
Exp Cell Res; 2019 Jan; 374(2):353-364. PubMed ID: 30562483
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
10. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.
Visnyei K; Onodera H; Damoiseaux R; Saigusa K; Petrosyan S; De Vries D; Ferrari D; Saxe J; Panosyan EH; Masterman-Smith M; Mottahedeh J; Bradley KA; Huang J; Sabatti C; Nakano I; Kornblum HI
Mol Cancer Ther; 2011 Oct; 10(10):1818-28. PubMed ID: 21859839
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
[TBL] [Abstract][Full Text] [Related]
12. High density is a property of slow-cycling and treatment-resistant human glioblastoma cells.
Sabelström H; Quigley DA; Fenster T; Foster DJ; Fuchshuber CAM; Saxena S; Yuan E; Li N; Paterno F; Phillips JJ; James CD; Norling B; Berger MS; Persson AI
Exp Cell Res; 2019 May; 378(1):76-86. PubMed ID: 30844389
[TBL] [Abstract][Full Text] [Related]
13. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoids promote a glioma stem cell-like phenotype and resistance to chemotherapy in human glioblastoma primary cells: Biological and prognostic significance.
Kostopoulou ON; Mohammad AA; Bartek J; Winter J; Jung M; Stragliotto G; Söderberg-Nauclér C; Landázuri N
Int J Cancer; 2018 Mar; 142(6):1266-1276. PubMed ID: 29067692
[TBL] [Abstract][Full Text] [Related]
15. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
18. Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin.
Jiang Y; Marinescu VD; Xie Y; Jarvius M; Maturi NP; Haglund C; Olofsson S; Lindberg N; Olofsson T; Leijonmarck C; Hesselager G; Alafuzoff I; Fryknäs M; Larsson R; Nelander S; Uhrbom L
Cell Rep; 2017 Jan; 18(4):977-990. PubMed ID: 28122246
[TBL] [Abstract][Full Text] [Related]
19. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
20. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
